

# TYKERB

## Prior Authorization Form

IF THIS IS AN URGENT REQUEST, Please Call UPMC Health Plan Pharmacy Services.

Otherwise please return completed form to:

UPMC HEALTH PLAN PHARMACY SERVICES

PHONE 800-979-UPMC (8762)

FAX 412-454-7722

**PLEASE TYPE OR PRINT NEATLY. Incomplete responses may delay this request.**

<b>Office Contact:</b>	<b>Provider Specialty:</b>
<b>Provider First Name:</b>	<b>Provider Last Name:</b>
<b>Provider Phone:</b>	<b>Provider Fax:</b>

<b>Patient Name:</b>	<b>Patient UPMC Health Plan ID Number:</b>	<b>Patient Age:</b>	<b>Patient DOB:</b>
----------------------	--	---------------------	---------------------

<b>Drug Requested:</b> <input type="checkbox"/> Brand <input type="checkbox"/> Generic	<b>Strength:</b>	<b>Frequency:</b>	<b>Expected length of therapy:</b>
---	------------------	-------------------	------------------------------------

*Generic equivalent drugs will be substituted for Brand name drugs unless you specifically indicate otherwise.*

<input type="checkbox"/> New medication	If ongoing, provide date started:	If medication is ongoing, Did member Show improvement while on therapy?	<input type="checkbox"/> Yes <input type="checkbox"/> No
---	-----------------------------------	---	---

Place of administration? <input type="checkbox"/> Physician Office <input type="checkbox"/> Hospital/Facility	Please indicate how medication will be billed: <input type="checkbox"/> Billed directly by the provider via JCODE Provide JCODE: _____ <input type="checkbox"/> Billed by a pharmacy and delivered to the provider <input type="checkbox"/> Billed by a pharmacy and delivered to the patient
---	---

Please provide pertinent progress notes and lab/radiology reports that describe the member's current disease status.

Chart documentation enclosed  Chart documentation not available

**Please indicate the diagnosis and answer the corresponding questions:**

<input type="checkbox"/> Breast Cancer	Please indicate disease status:	<input type="checkbox"/> Advanced	<input type="checkbox"/> Metastatic	
	Please indicate stage:			
	Is Tykerb being used in combination with capecitabine (Xeloda)?		<input type="checkbox"/> Yes <input type="checkbox"/> No	
	Is Tykerb being used in combination with letrozole (Femara)?		<input type="checkbox"/> Yes <input type="checkbox"/> No	
	Is cancer associated with HER2 over-expression? <input type="checkbox"/> Yes <input type="checkbox"/> No			
	What is the hormone receptor status?		Estrogen Receptor:	Progesterone Receptor:
			<input type="checkbox"/> Positive <input type="checkbox"/> Negative	<input type="checkbox"/> Positive <input type="checkbox"/> Negative
	Is member postmenopausal? <input type="checkbox"/> Yes <input type="checkbox"/> No			

Has member had prior therapy with antracycline, taxane, and trastuzumab (Herceptin)?  
 Yes  No if yes, please list below:

Medication Name	Strength/Frequency	Dates of Therapy	Reason for Discontinuation

Other Diagnosis, please list: \_\_\_\_\_ Please provide clinical literature/studies to support request for off-label use.  
 Clinical literature/studies enclosed  Clinical literature/studies not available

**Is Tykerb being used in combination with any other therapies?  Yes  No If yes, please list below.**

Medication Name	Strength/Frequency	Dates of Therapy

**Please list below any other previous therapies tried:**

Medication Name	Strength/Frequency	Dates of Therapy	Reason for Discontinuation

**Please provide any additional information which should be considered in the space below:**